Study of MK-6552 in Participants With Narcolepsy Type 1 (MK-6552-004)
Status:
Recruiting
Trial end date:
2024-12-05
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics (PK), and
pharmacodynamics (PD) of MK-6552 in participants with Narcolepsy Type 1 (NT1). Part 1 will
evaluate safety, tolerability, and PK of MK-6552 after administration of ascending doses in a
single day to support a dose level decision for Part 2. Part 2 will investigate the PD of
MK-6552 after single-day and multiple-day administration. Participants who complete Part 1
and demonstrate that they are able to tolerate at least one dose level of MK-6552 will
participate in Part 2.